Loginx

If you have an account with us, please log in.

Create an AccountForgot Your Password?

* Required Fields

Create an Accountx

* Required Fields

Back to Login

Forgot Your Password?x

Please enter your email address below. You will receive a link to reset your password.

* Required Fields

Back to Login

JAK



20 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Product Information
A10095

AT9283

AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases associated with myeloid cell proliferation. Learn More
A10104

AZ-960

AZ-960 is a potent, selective and ATP competitive JAK2 inhibitor that inhibits JAK2 kinase with a Ki of 0.45 nM in vitro and induces growth arrest and apoptosis in adult T-cell leukemia (ATL) cell. Learn More
A10110

AZD1480

AZD1480 is a novel potent small JAK2 inhibitor with an IC50 of 0.26 nM. Learn More
A11329

Baricitinib (LY3009104)

Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). Learn More
A15014

Baricitinib phosphate

Baricitinib phosphate is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Learn More
A11241

BMS-911543

BMS-911543 is an orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. Learn More
A12808

CEP33779

CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM. Learn More
A10241

CP-690550 (Tofacitinib citrate)

CP-690550 (Tofacitinib citrate) is an orally available, highly selective inhibitor of the Janus kinase (JAK) family of enzymes. Learn More
A10263

Cyt387 (Momelotinib)

CYT387 is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. Learn More
A13162

GLPG0634

GLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases. Learn More
A11041

INCB018424 (Ruxolitinib)

INCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively; Learn More
A13457

JAK Inhibitor I

JAK Inhibitor I is a potent, reversible, cell-permeable, and ATP-competitive inhibitor of JAK1, JAK2, and JAK3. Learn More
A10546

LY2784544

LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders. Learn More
A11193

NVP-BSK805

NVP-BSK805 is a potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor that potently suppressed recombinant human erythropoietin-induced polycythemia and extramedullary erythropoiesis in mice and rats.

Learn More
A13082

PF-03394197 (oclacitinib)

PF-03394197 (oclacitinib) is a potent JAK/STAT inhibitor Learn More
A11082

TG-101348

TG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity. Learn More
A11180

TG101209

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

Learn More
A14049

WHI-P 154

WHI-P 154 is a JAK3 inhibitor with IC50 = 1.8uM. WHI-P 154 also Inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro. Learn More
A11795

WP1066

WP1066 is a novel JAK2 inhibitor and it suppresses proliferation and induces apoptosis in eythroid human cells carrying the JAK2 V617F mutation. Learn More
A12394

XL019

XL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. Learn More

20 Item(s)

per page

Set Descending Direction
JAK

Minimal Price: $50.00